FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Novartis | flu vaccine | Kathleen Sebelius

HHS chief promises cell-based flu vax in 2011

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools
  • Subscribe
  • Email
  • Print
  • Contact Author
  • Reprint

HHS Secretary Kathleen Sebelius says that the agency's $487 million contract with Novartis is helping spur development of a new cell-based flu vaccine that is scheduled to be on the market in time for the 2011/2012 flu season. But Novartis officials say they can't commit to that timetable as long as the FDA remains in control of vaccine approvals.

Novartis is "scheduled to be online to apply for licensing early in 2011 for cell-based seasonal vaccine, and a licensed vaccine is expected to be marketed for the 2011-12 flu season," Sebelius told a Senate committee, according to a report from CIDRAP.

If so, the arrival of a cell-based flu vaccine would mark a major step forward in the country's efforts to upgrade the technology used in developing and manufacturing huge quantities of vaccines. The U.S. has yet to license a cell-based vaccine, unlike Europe. Sebelius committed HHS to modernizing the field and gaining more American manufacturing operations after the swine flu pandemic revealed just how slowly it can take to arm a country against a virus.   

"Novartis plans to file for cell-based vaccine technology in the US in the first half of 2011," the company confirmed, "but approval is contingent upon FDA review, so we cannot confirm when cell-based vaccines would be on the market in the US."

- here's the story from CIDRAP

Related Articles:
Expect lower flu vax demand in Europe next year
Novartis VC arm backs fledgling universal flu vax
Plant-based H1N1 vax starts clinical trial
NanoBio unveils promising data on next-gen vaccine


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Novartis   flu vaccine   Kathleen Sebelius